Latest news with #Massachusetts
Yahoo
36 minutes ago
- Entertainment
- Yahoo
Boston Rob reveals why he turned down 'Survivor 50' casting: 'I have played so many times'
Boston Rob Mariano is taking full responsibility for his absence from the Survivor 50 cast list. The five-time Survivor player and one-time winner posted a lengthy statement to his Instagram on Friday revealing why he turned down a spot on the coveted milestone season's cast list. "Wow!!! I got all of your DM's and messages so so many thank you all!!" Mariano wrote. "But literally don't be mad @survivorcbs and @jeffprobst early on they called and asked… I just felt like I have played so many times and I am truly fulfilled with my Survivor Journey." The legendary player, who was the first to ever hit five seasons on the long-running CBS series, added that he hoped dropping out of season 50 would allow someone else to get another chance at the title of Sole Survivor. "I wanted my spot to go to someone else that deserved another chance!" he wrote. "I've gotten so much out of Survivor. It will always be a part of who I am! I'm eternally grateful. Like I said ..It's gonna be OK. I feel like something good is coming!!!" Survivor 50 won't air until 2026, but host and showrunner Probst already announced the full cast on Wednesday. The supersized group of 24 returning players is the series' biggest cast ever, featuring contestants going all the way back to season 1 of Survivor: Borneo (Jenna Lewis-Dougherty) as well as two yet-unnamed competitors from Survivor 49, which just filmed a few weeks ago and will air this fall on CBS. The cast also features two legends competing for the fifth time, Cirie Fields and Ozzy Lusth, tying Mariano's record as the most seasons ever played. Other notable returning players include The White Lotus creator Mike White and recent winners Dee Valladares (Survivor 45) and Kyle Fraser (Survivor 48). Mariano previously told Entertainment Weekly that he was ready to field Survivor 50 alliance requests. "I'm stirring it up on social media like I like to do," he said in 2024. "So slide into the DMs, all you former players, and we'll let you know whether or not you can get in the alliance or not. Actually, talk to my secretary, Sandra [Diaz-Twine]. She's fielding all the requests." However, he previously told EW a few months earlier that he was not open to appearing on the show the way it's currently constructed. "I mean, in what capacity?" he said. "As a contestant playing with everyone else, it just feels like we've been there and we've done that." . He added that he was still down to appear on the show either in a mentor role again (as he appeared on the Island of the Idols season) or another way in which he will not be immediately eliminated due to his massive threat level. "I've always said it would take some kind of unique format change to make me go back and compete over there," he said. "Something would have to happen, otherwise we're faced with the same situation where they gang up on me and want to get me out, or keep me around for a little bit, or whatever... I think there would have to be a pretty dynamic format shift to get me excited to get back out there." Mariano also recently competed on Peacock's The Traitors and NBC's Deal or No Deal Island, but came up short of winning either series. Read the original article on Entertainment Weekly
Yahoo
an hour ago
- Health
- Yahoo
Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE
mNEXSPIKE becomes Moderna's third FDA-approved product CAMBRIDGE, MA / / May 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mNEXSPIKE® (mRNA-1283), a new vaccine against COVID-19, for use in all adults 65 and older, as well as individuals aged 12-64 years with at least one or more underlying risk factor as defined by the Centers for Disease Control and Prevention (CDC).[1] "The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19," said Stéphane Bancel, Chief Executive Officer of Moderna. "COVID-19 remains a serious public health threat, with more than 47,000 Americans dying from the virus last year alone. We appreciate the FDA's timely review and thank the entire Moderna team for their hard work and continued commitment to public health." The FDA's approval of mNEXSPIKE is based on results from a randomized, observer-blind, active-controlled Phase 3 clinical trial ( Identifier: NCT05815498), which enrolled approximately 11,400 participants aged 12 years and older. The primary efficacy objective in this study was to demonstrate the non-inferior vaccine efficacy against COVID-19 starting 14 days after mNEXSPIKE compared to that after the comparator vaccine, mRNA-1273 (Spikevax®), Moderna's original COVID-19 vaccine. Participants received either a 10 μg dose of mRNA-1283 or a 50 μg dose of mRNA-1273. mRNA-1283 showed a 9.3% higher relative vaccine efficacy (rVE) compared to mRNA-1273 in individuals aged 12 years and older, and in a descriptive sub-group analysis, a 13.5% higher rVE in adults aged 65 and older. In the Phase 3 trial, mRNA-1283 was found to have a similar safety profile to mRNA-1273, with fewer local reactions and comparable systemic reactions. The most commonly solicited side effects were injection site pain, fatigue, headache and myalgia. Moderna expects to have mNEXSPIKE available for eligible populations in the U.S. for the 2025-2026 respiratory virus season, alongside Spikevax and mRESVIA®, the Company's approved respiratory syncytial virus (RSV) vaccine. mRNA-1283 is under review with regulators in multiple markets around the world. About ModernaModerna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. mNEXSPIKE®, mRESVIA® and Spikevax®are registered trademarks of Moderna. INDICATION mNEXSPIKE is a vaccine to protect against COVID-19. mNEXSPIKE is for people who have received a COVID-19 vaccine before and are: • 65 years of age and older, or • 12 years through 64 years of age at high risk for severe COVID-19. Vaccination with mNEXSPIKE may not protect all people who receive the vaccine. IMPORTANT SAFETY INFORMATION You should not get mNEXSPIKE if you hada severe allergic reaction after a previous dose of either mNEXSPIKE, SPIKEVAX (COVID-19 Vaccine, mRNA), or any Moderna COVID-19 vaccine or to any ingredient in these vaccines. What are the risks of mNEXSPIKE?There is a very small chance that mNEXSPIKE could cause a severe allergic reaction. A severe allergic reaction would usually occur within a few minutes to 1 hour after getting a dose of mNEXSPIKE. For this reason, your healthcare provider may ask you to stay for a short time at the place where you received your vaccine. Signs of a severe allergic reaction can include: Trouble breathing Swelling of your face and throat A fast heartbeat A rash all over your body Dizziness and weakness Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received mRNA COVID-19 vaccines. Myocarditis and pericarditis following mRNA COVID-19 vaccines have occurred most commonly in males 12 years through 24 years of age. You should seek medical attention right away if you or your child has any of the following symptoms after receiving the vaccine, particularly during the 2 weeks after receiving a dose of the vaccine: Chest pain Shortness of breath Feelings of having a fast-beating, fluttering, or pounding heart Side effects that have been reported in clinical trials with mNEXSPIKE include: Injection site reactions: pain, tenderness and swelling of the lymph nodes in the same arm of the injection, swelling (hardness), and redness. General side effects: fatigue, headache, muscle pain, joint pain, chills, nausea, vomiting, and fever Tell your vaccination provider about all of your medical conditions, including if you: have any allergies had a severe allergic reaction after receiving a previous dose of any COVID-19 vaccine have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart) have a fever have a bleeding disorder or are on a blood thinner are immunocompromised or are on a medicine that affects your immune system are pregnant or plan to become pregnant are breastfeeding have received any other COVID-19 vaccine have ever fainted in association with an injection These may not be all the possible side effects of mNEXSPIKE. Ask your healthcare provider about any side effects that concern you. You may report side effects to Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967 or Please click for mNEXSPIKE Full Prescribing Information. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the efficacy, safety and tolerability of mNEXSPIKE; and the availability of Moderna's respiratory vaccines for the 2025-2026 season. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release. Moderna ContactsMedia:Chris RidleyHead of Global Media Relations+1 Investors:Lavina TalukdarSenior Vice President & Head of Investor Relations+1 [1] SOURCE: Moderna, Inc. View the original press release on ACCESS Newswire Sign in to access your portfolio
CBS News
2 hours ago
- Health
- CBS News
Massachusetts high school baseball player celebrates end of cancer treatment with teammates
The baseball field at North Reading High School has been getting a lot of use this season. They've made it to the playoffs after all. But their inspiration to play better and practice harder has come from a teammate who was not on the field this year. Brady Cullen is a 16-year-old sophomore at NRHS who would normally be finishing a spring season in his position on third base. Last August, he and his family got a devastating diagnosis of a brain tumor (pilocytic astrocytoma.) The non-cancerous tumor was too close to his brain stem to be operated on. After months of appointments, his medical team at Mass General Hospital recommended radiation to stop it from growing. Brady rings bell after six weeks of radiation This week, Brady finished his 30th session. Six weeks of radiation, five days a week. When Brady rang the bell in the halls of MGH he wasn't alone. "It was unbelievable. It was hard not to just break down right there in the hospital," Brady recalled. When he turned around, he found his entire baseball team lining up in the halls. Cheering him on as he left his last appointment in his months-long battle. North Reading sophomore Brady Cullen is greeted by his baseball teammates after completing his cancer treatments at Mass General Brigham. Mass General Brigham "They are my brothers and to see that combined with my family, it was so special," he said. "It just made me realize I am at peace with myself. I am at peace with my journey. I am where I want to be I am where I need to be and that will never change." Team makes trip to Boston Eric Archambault is the head coach of the North Reading High School baseball team. Coach Arch, as he's called, said it wasn't a question of whether the team would make the trip to Boston on Thursday. He said Brady never missed school and rarely missed practice or games as a team manager during his treatments. "We are seeing a kid with our very eyes attack a situation that nobody wishes for, and he takes it head on every single day," said Archambault. "Everyone wasn't supporting Brady just because of the diagnosis. We are supporting Brady because of who he is. He has touched everyone on the team throughout the years, and we look up to him." Brady said he plans to work with a physical therapist and get back out on the field. Overwhelmed and thankful for the army of support he had from his team and community. "Life is the most precious and beautiful thing, and it can be taken away so fast and I want them to realize that, embrace hardships because hardships build your character and they build who you are, and they make you stronger than ever," Brady said. "I know for damn sure I am stronger than ever from this. I am proud to say I came out on top with a whole new perspective on live and a new appreciation for it."
Washington Post
3 hours ago
- General
- Washington Post
Federal officials to vet social media accounts of visa applicants heading to Harvard
Federal officials are set to start reviewing the social media accounts of visa applicants who plan to attend, work at or visit Harvard University for any signs of antisemitism, marking the latest development in a clash between the Trump administration and the Ivy League school. A cable sent Friday signed by Secretary of State Marco Rubio and obtained by The Associated Press accused the university of failing to keep violence and antisemitism off campus. It said the vetting measure will help consular officers identify applicants with a history of those offenses 'and to duly consider their visa eligibility under U.S. immigration law.'
Associated Press
3 hours ago
- Business
- Associated Press
Federal officials to vet social media accounts of visa applicants heading to Harvard
Federal officials are set to start reviewing the social media accounts of visa applicants who plan to attend, work at or visit Harvard University for any signs of antisemitism, marking the latest development in a clash between the Trump administration and the Ivy League school. A cable sent Friday signed by Secretary of State Marco Rubio and obtained by The Associated Press accused the university of failing to keep violence and antisemitism off campus. It said the vetting measure will help consular officers identify applicants with a history of those offenses 'and to duly consider their visa eligibility under U.S. immigration law.' The measure was sent to all U.S. embassies and consulates, and it takes effect immediately. It will serve as a pilot program that could be expanded more broadly, according to the cable. Harvard did not immediately respond to an email requesting comment. The university was the first to openly defy White House demands for changes at elite schools the administration has criticized as hotbeds of liberalism and antisemitism. Since then, the federal government has stripped the nation's oldest and wealthiest university of $2.6 billion in federal grants, forcing it to self-fund much of its research operation. President Donald Trump has said he wants to revoke the university of its tax-exempt status. Last week, Harvard sued the federal government after Department of Homeland Security Secretary Kristi Noem revoked its ability to host foreign students at its campus in Cambridge, Massachusetts. A federal judge has since blocked the move. More than a quarter of Harvard's student body at its Cambridge campus are foreign students. Most are graduate students, coming from more than 100 countries. Earlier this week, the State Department paused the scheduling of new visa interviews for foreign students looking to study in the U.S., saying it was preparing to expand the screening of their activity on social media. It's unclear whether that pause has been lifted. The new measure expands on Trump's previous administration introducing reviews of visa applicants' social media accounts. It remained in place during former President Joe Biden's administration. The measure instructs officials to note whether a visa applicant does not have an online presence or has their social media accounts set to private and whether that 'may be reflective of evasiveness and call into question the applicant's credibility.' 'If you are not satisfied that the applicant credibility, and to your personal satisfaction, meets the standards required by the visa classification for which he is applying, refuse the applicant,' the cable said. Officials have also been instructed to go beyond just reviewing social media accounts and to conduct a broader investigation of the person's online presence, according to the cable.
